Resultados de la búsqueda 91-100 of 6481 for Absence

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... absent (i.e., after ... The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol-defined dose (HPDD); in the absence ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  3. Neurología - Ensayos clínicos - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  5. JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

  10. Obstetricia y Ginecología - Ensayos clínicos

    All offspring will undergo postnatal genetic testing for the parental mutation as the gold standard for diagnosing the presence or absence of LQTS.